Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
PLoS One ; 13(1): e0190768, 2018.
Article in English | MEDLINE | ID: mdl-29385147

ABSTRACT

BACKGROUND: The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the tolerability and safety of self-titrated nabiximols vs. placebo among 40 treatment-seeking cannabis-dependent participants. METHODS: Subjects participated in a double blind randomized clinical trial, with as-needed nabiximols up to 113.4 mg THC/105 mg CBD or placebo daily for 12 weeks, concurrently with Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT). Primary outcome measures were tolerability and abstinence, secondary outcome measures were days and amount of cannabis use, withdrawal, and craving scores. Participants received up to CDN$ 855 in compensation for their time. RESULTS: Medication was well tolerated and no serious adverse events (SAEs) were observed. Rates of adverse events did not differ between treatment arms (F1,39 = 0.205, NS). There was no significant change in abstinence rates at trial end. Participants were not able to differentiate between subjective effects associated with nabiximols or placebo treatments (F1,40 = 0.585, NS). Cannabis use was reduced in the nabiximols (70.5%) and placebo groups (42.6%). Nabiximols reduced cannabis craving but no significant differences between the nabiximols and placebo groups were observed on withdrawal scores. CONCLUSIONS: Nabiximols in combination with MET/CBT was well tolerated and allowed for reduction of cannabis use. Future clinical trials should explore the potential of high doses of nabiximols for cannabis dependence.


Subject(s)
Cannabidiol/therapeutic use , Cognitive Behavioral Therapy , Dronabinol/therapeutic use , Marijuana Abuse/therapy , Motivation , Adult , Craving , Double-Blind Method , Drug Combinations , Female , Humans , Male , Middle Aged , Pilot Projects , Placebos , Substance Withdrawal Syndrome/therapy , Young Adult
3.
J Addict Med ; 10(4): 274-9, 2016.
Article in English | MEDLINE | ID: mdl-27261670

ABSTRACT

OBJECTIVES: Cannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel approaches and further investigation of promising pharmacotherapy. In this case series, we assessed the use of self-titrated dosages of Sativex (1:1, Δ-tetrahydrocannabinol [THC]/cannabidiol [CBD] combination) and motivational enhancement therapy and cognitive behavioral therapy (MET/CBT) for the treatment of cannabis dependence among 5 treatment-seeking community-recruited cannabis-dependent subjects. METHODS: Participants underwent a 3-month open-label self-titration phase with Sativex (up to 113.4 of THC/105 mg of CBD) and weekly MET/CBT, with a 3-month follow-up. RESULTS: Sativex was well-tolerated by all participants (average dosage 77.5 THC/71.7 mg CBD). The combination of Sativex and MET/CBT reduced the amount of cannabis use and progressively reduced craving and withdrawal scores. THC/CBD metabolite concentration indicated reduced cannabis use and compliance with medication. CONCLUSIONS: In summary, this pilot study found that with Sativex in combination with MET/CBT reduced cannabis use while preventing increases in craving and withdrawal in the 4 participants completing the study. Further systematic exploration of Sativex as a pharmacological treatment option for cannabis dependence should be performed.


Subject(s)
Cognitive Behavioral Therapy/methods , Marijuana Abuse/drug therapy , Motivational Interviewing/methods , Outcome Assessment, Health Care , Plant Extracts/pharmacology , Secondary Prevention/methods , Adult , Cannabidiol , Combined Modality Therapy , Dronabinol , Drug Combinations , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Plant Extracts/administration & dosage , Recurrence
4.
CMAJ ; 183(18): 2149-50, 2011 Dec 13.
Article in English | MEDLINE | ID: mdl-22159361

ABSTRACT

The annual "Roll Up the Rim to Win" contest at Tim Hortons restaurants provides customers the opportunity to win prizes. This study investigated win ratios, prize types and patterns of coffee consumption.


Subject(s)
Beverages , Coffee , Eating/physiology , Awards and Prizes , Canada/epidemiology , Follow-Up Studies , Humans , Prevalence , Prospective Studies , Reference Values , Risk Factors , Surveys and Questionnaires , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...